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Regulation of sympathoadrenal activity has been a long-time target in
the management of hypertension. Regulation of b-adrenoceptor (bAR)
function has been the most therapeutically important of these targets.
The development of effective antihypertensive treatments based on
bAR antagonism paralleled the elucidation of the molecular basis of
b-adrenergic effects by the family of bARs, which are members of the
G-proteinecoupled receptor (GPCR) superfamily. bARs serve as the
extracellular face of the transmembrane signalling pathway that re-
sults in the consequent activation of heterotrimeric G-proteins and the
activation of several other newly appreciated signalling molecules that
include b-arrestins and GPCR kinases (GRKs). The aggregate effect of
the activation of these signalling pathways mediates the response to
bAR activation. Paradoxically, the hypertensive state is characterized
by impaired bAR responsiveness. This defect is common to many other
receptor systems linked to the stimulator G protein (Gs) and adenylyl
cyclase activation. This impairment is principally mediated by
receptoreG-protein uncoupling, which has been linked to increased
expression and activity of GRK2.Received for publication January 9, 2014. Accepted January 31, 2014.
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ORESUME
La regulation de l’activite sympathicoadrenergique a longtemps ete une
cible dans la prise en charge de l’hypertension arterielle. La regulationde
la fonction du recepteur b-adrenergique (RbA) a ete la cible la plus
importante sur le plan therapeutique. Le developpement de traitements
antihypertenseurs efﬁcaces bases sur les antagonistes du RbA se
deroulait parallèlement à l’elucidation de la basemoleculaire des effets
b-adrenergiques par la famille des RbA, qui sont des membres de la
superfamille des recepteurs couples auxproteinesG. LesRbA servent de
face extracellulaire de la voie transmembranaire de signalisation qui
entraîne l’activation des proteines G heterotrimeriques et l’activation
de plusieurs autres nouvelles molecules de signalisation, dont les b-
arrestines et les kinases des recepteurs couples aux proteines G (KRG).
L’effet cumule de l’activation de ces voies de signalisation sert de
mediateur à la reponse à l’activation du RbA. Paradoxalement, l’etat
hypertensif est caracterise par la diminution de la reactivite du RbA.
Cette anomalie est commune à plusieurs autres systèmes de recepteurs
lies à l’activation de la proteine G stimulatrice (Gs) et de l’adenylcyclase.
Cette deterioration est principalement mediee par le decouplage du
recepteureproteine G, qui a ete lie à l’augmentation de l’expression et
de l’activite de la KRG2.The role of the sympathetic nervous system, acting predom-
inantly through catecholamine-mediated adrenoceptor acti-
vation in the pathogenesis and maintenance of hypertension,
has long been appreciated. Further, before the development of
the renin-angiotensin system blockers, the adrenergic receptors
(adrenoceptors [ARs]) were unarguably the most important
targets for drugs in the management of hypertension. The
earliest antihypertensive drugs, such as guanethidine andreserpine, targeted pathway regulation of adrenergic hormone
levels (ie, regulation of norepinephrine and to a lesser extent
epinephrine).1 This target followed from the even earlier
appreciation of the role of the sympathetic nervous system as
an important pathway in the pathogenesis and maintenance of
hypertension. One of the early approaches in the management
of severe hypertension was surgical interruption of the sym-
pathetic nervous system through the so-called lumbar sympa-
thectomy procedure.2 This surgical approach was effective
but was associated with very severe negative consequences,
including neuropathic pain, sexual dysfunction, and severe
sweating. Thus, surgical sympathectomy was eventually su-
perseded by the development of drugs acting to reduce central
sympathetic activity through inhibition of neurotransmitter
release. However, with the increasing appreciation of the
limitations and adverse effects associated with this class ofpen access under CC BY-NC-ND license.
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searched for more direct blockers of the adrenergic receptorsd
speciﬁcally the a- and b-adrenoceptors (ARs).
The role of regulation of aARs in the management of
hypertension has remained limited. The blood pressuree
regulating effect of a2AR activation (with drugs like clonidine)
is primarily through regulation of presynaptic inhibition of
neurotransmitter releasedat least in the setting of an intact
central nervous system.3 However, despite their effectiveness,
the use of a2AR agonists in hypertension has been limited by
their side effects, ie, drowsiness, fatigue, and dry mouth.3
Similarly, the use of a1AR antagonists such as prazosin,
doxazosin, and terazosin has remained marginal. These drugs
were initially promoted as having the “perfect proﬁle” in the
management of patients with hypertensiondie, effective
blood pressure lowering with favourable effects on lipid pro-
ﬁles and insulin sensitivity/glucose metabolism.4 However,
the recognition of several important factors led to the current
limited use of a1AR antagonists. These factors included the
development of tolerance to their antihypertensive effects,
their lesser effectiveness compared with other antihypertensive
classes, and an unfavourable side effect proﬁle including
orthostatic hypotension and nasal congestion.4 Perhaps the
coup de grâce for this class of drugs came from its early
withdrawal from the ALLHAT (Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial) study.
This decision was based on the recognition of the futility
of carrying on with the doxazosin arm of the study.5,6 This
was most likely related to its lesser blood pressureelowering
effectiveness, as well as the associated increased risk of pe-
ripheral edema, which may have been misdiagnosed as heart
failure. The limitations of both a1AR antagonists and a2AR
agonists are recognized in the Canadian Hypertension Edu-
cation Program by its recommendations for the use of both of
these classes of drugs as third- or fourth-line therapy.7
In contrast, bAR antagonists, which act primarily by
reducing cardiac output and renin release, have remained
important components of antihypertensive therapy, as well as
being important in the treatment of patients with coronary
artery disease and cardiac arrhythmias.8 This is reﬂected in
their ﬁrst-line status as recommended therapy in the man-
agement of hypertension in younger patients and in their use
in patients with coronary artery disease comorbidities.7 In part
related to the therapeutic importance of this class of drugs,
much of what we know about the structure and function of
ARs and the receptor superfamily to which they belong, ie, the
G-proteinecoupled receptors (GPCRs), comes from the study
of the structure and function of bARs. Further, much of our
basic understanding of how drugs interact with these
receptorsdas agonist, antagonists, inverse agonists, biased
agonists (as will be discussed further on)dis based on the
study of bARs. Consequently, we will summarize in this short
review the molecular structure of bARs, how they interact with
ligands, and the implication of their activation and regulation
normally and in the setting of cardiovascular disease.bAR Subtypes
During thepast 50 years, new techniques involvingmolecular
pharmacology and radioligands have allowed investigators to
deﬁne more precisely the nature and role of the differentsubtypes of ARs. Using pharmacologic, biochemical, and mo-
lecular biological techniques, 3 subtypes of bARs have now been
effectively characterized. The b1AR is mainly found in the heart
and represents 75%-80%of the cardiacbARmass.9 Theb2AR is
located in a number of sites, such as the lungs, uterus, kidneys,
liver, and peripheral blood vessels.10 Most recently, the b3AR
was identiﬁed initially in brown adipose tissue and subsequently
in a range of tissues.11,12 The molecular basis for the roles and
actions of these receptor subtypes has now been well described.
Molecular Structure of the bARs
The 3 bAR subtypes (b1, b2, b3) are each coupled to the
activation of adenylyl cyclase and the formation of cyclic
adenosine monophosphate (cAMP) through their interaction
with the heterotrimer G-protein GaS.
13 The elucidation of the
molecular structure of the b2AR has been the subject of
intense investigation for more than 3 decades. The cDNA
encoding the b2AR was ﬁrst cloned in 1985 and revealed that
the receptor was the second member of a large membrane
receptor superfamily,14 which is now known to be comprised
of more than 650 gene products, with alternative splicing
resulting in the generation of at least 1000-2000 distinct re-
ceptor proteins.15,16 The bARs, like all GPCRs, are composed
of 7 transmembrane-spanning a-helical domains connected
by 3 extracellular loops and 3 intracellular loop domains. The
amino-terminus of the receptor is oriented to the extracellular
space of the cell, whereas the carboxyl-terminal tail of the
b2AR is intracellularly localized. Recently, elegant crystallo-
graphic structures for the b2AR bound to agonists, antago-
nists, and GaS have provided important new insights into the
mechanisms that mediate the association of b-adrenergic li-
gands with the receptor and have allowed the elucidation of
how ligands induce conformational changes in the b2AR,
allowing it to associate with and activate GaS.
17-20
Ligand binding to the b2AR involves the association of
agonist and antagonist drugs within a binding pocket formed
by the 7 transmembrane domains of the receptor. The speci-
ﬁcity of ligand binding and whether drugs function as either
agonists or antagonists is dependent on their relative ability
to stabilize either the active or inactive conformations of the
receptor. This is dictated by the manner in which individual
b-adrenergic drugs are accommodated within the pocket by
amino acid residues contributing to the formation of the ligand
binding pocket. The binding of agonist drugs results in a
shifting of the relative orientation of the transmembrane do-
mains 5 and 6 with respect to one another, and this information
is transmitted as alterations in the intracellular loop and
carboxyl-terminal tail domains of the receptor that are thought
to be required for G-protein activation.19 In contrast, antago-
nist drugs appear to stabilize the inactive conformation of the
receptor, reducing both the probability that the receptor will
isomerize to an active state or bind an agonist drug, or both.
Receptor-Effector Coupling of bARs
The traditional view of b-adrenoceptor coupling to the
effector pathways is the consequence of its ability to couple to
and activate GaS alone. GaS is a heterotrimeric G-protein that
is composed of a, b, and l subunits. In the inactive confor-
mation, the a-subunit is bound to GDP and is associated with
the bl-subunit that forms a stable dimeric protein complex
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tion of bARs and their subsequent interactions with GaS
result in the exchange of guanosine diphosphate (GDP) for
guanosine triphosphate on the a-subunit of the heterotrimeric
G-proteins, which results in a profound change in the struc-
ture of the a-subunit.20 This conformational change facilitates
the activation of the a-subunit, allowing it to interact with
and activate its downstream effector protein adenylyl cyclase.
This conformational change also releases the bl dimer,
allowing it to function as an activator of cell signalling through
multiple effector partners.21
The activation of adenylyl cyclase results in the synthesis of
cAMP from adenosine triphosphate. The second messenger
molecule cAMP then functions to activate cAMP-dependent
protein kinase A (PKA) by binding to the regulatory sub-
units of the kinase. This results in the release and activation
of the catalytic kinase domain.13 The PKA catalytic domain
subsequently contributes to the phosphorylation and activa-
tion of a variety of intracellular signalling proteins and tran-
scription factors that contribute to the biological consequences
of b-adrenoceptor activation.
Agonist activation of a bAR also engages a number of
additional protein-protein interactions, the post-translational
modiﬁcation of the receptor, and its subsequent inactivation
or inability (or both) to stimulate prolonged cAMP formation
responses. b1AR and b2AR can be phosphorylated by PKA
by virtue of the fact that they encode PKA phosphorylation
consensus sites in their third intracellular loop and proximal
carboxyl-terminal domains. The post-translational modiﬁca-
tion of serine and threonine residues within these consensus
sequences with addition of a phosphate group alters the
structure of the receptors such that they are unable to interact
with GaS to activate the GDP for guanosine triphosphate
exchange cycle that is required for G-protein activation.22-25
In contrast, the b3AR does not contain consensus sites for
this type of desensitization and does not serve as a substrate for
PKA-mediated desensitization.26
It is now recognized that the engagement of b-adrenergic
ligands by bARs results in receptor desensitization but also
initiates the activation of additional cellular processes, including
the endocytosis of the receptor to the endosomal compartment
through clathrin-coated vesicles and the coupling of the receptor
toG-proteineindependent signal transduction pathways.23,24,27
Activation of the b2AR results in the phosphorylation of serine
and threonine residues in the carboxyl-terminal tail of the re-
ceptor by GPCR-speciﬁc protein kinases.23-25,28 Agonist acti-
vation and GPCR kinase (GRK)-dependent phosphorylation
promotes the membrane translocation of cytosolic b-arrestin
proteins that bind to the intracellular face of the receptor to
prevent G-protein interactions. Receptor activationemediated
recruitment of b-arrestins not only results in the desensitization
of b2AR receptor signalling but also allows for b-arrest-
inemediated facilitation ofb2AR endocytosis.
28 This occurs via
b-arrestin association with the b2-adaptin subunit of the het-
erotrimeric adaptor complex and clathrin.29,30
b-Arrestin proteins also play a predominant role in
coupling bARs, and GPCRs in general, to the activation of
intracellular signal transduction pathways that are hetero-
trimeric G-protein independent. The ﬁrst evidence indicating
that b-arrestins served as intracellular signalling molecules
came from studies with the b2AR, in which the b2AR wasshown to activate the ERK1/2 pathway through a b-arrestin-
and Src-dependent mechanism.31 b-Arrestins have been
demonstrated to play a role in receptor-mediated activation of
kinases such as Src, ERK1/2, Raf, Jnk3, and Akt, as well as
regulating the activity of small G-proteins such as Ral, Arf6,
and Rho through their association with guanine nucleotide
exchange factors such as ARNO and RalGDS.31-39
A newly appreciated aspect of GPCR signalling is that
some ligands that normally function as antagonists to block
G-protein signalling pathways may also function as agonists
on alternative signalling pathways in the same cell.40-43
This so-called biased agonism is particularly important with
respect to b-arrestin signalling and is a target for the treatment
of heart failure and hypertension. For example, it has been
demonstrated that the b-blocker carvedilol antagonizes the
Gs-coupling of b2ARs but stimulates GRK-mediated phos-
phorylation of the receptor, b-arrestin recruitment, and
ERK1/2 phosphorylation.44,45
Nature of Ligand Receptor Interactions
The elucidation of the crystal structure of b2AR has
facilitated our understanding of the mechanisms by which
drugs bind to b-adrenergic receptors to either stimulate or
antagonize their activity in cells and tissues.17-20 Originally, b-
adrenergic drugs fell into 3 general categories: (1) full agonists,
(2) partial agonists, and (3) antagonists. However, more recent
pharmacologic studies have expanded these categories to
include inverse agonists and biased agonists (Fig. 1).
1. Agonists are drugs that bind to receptors and facilitate the
ability of the receptor to adopt a thermodynamic state that
favours the activation of the heterotrimeric G-protein. Full
agonists are drugs that fully activate the receptor in a sig-
nalling assay, and partial agonists produce submaximal
activation of receptor signalling even when all receptors are
bound with ligand. The submaximal receptor activation
mediated by a partial agonist may result from a faster
dissociation rate from the receptor than that produced by
full agonists, or partial agonists may stabilize an interme-
diary conformation of the receptor that is unable to
maximally activate the heterotrimeric G-protein.46
2. Antagonists or “neutral” antagonists are drugs that bind a
receptor and have no efﬁcacy in that they neither activate
the receptor nor block the intrinsic or basal activity of the
receptor. However, they do block the activity of full ago-
nists, partial agonists, and inverse agonists by competing
for binding to the receptor ligand binding pocket.
3. Inverse agonists were ﬁrst described when it was discovered
that many GPCRs, including b-adrenergic receptors, have
basal or intrinsic activity. Nuclear magnetic resonance
studies have revealed that the activation of heterotrimeric
G-proteins by receptors involves an equilibrium between
conformational states that does not necessitate agonist
binding, but by virtue of the ﬂexibility of the receptor
protein structure, a small fraction of receptors can adopt an
activated state in the absence of agonist.46 Consequently,
many drugs that were ﬁrst identiﬁed as antagonists because
of their ability to block full and partial agonist activity are
now classiﬁed as inverse agonists because of the fact that
they favour the ability of the receptor to adopt an inactive
conformation and reduce the intrinsic or basal activity of
Figure 1. The spectrum of b-adrenoceptor (bAR)eligand interactions:
from full agonists to inverse agonists. (A) Receptor activation state.
Under basal conditions, GPCRs oscillate between active (R*) and
inactive forms (R). Full agonists stabilize the active form, and inverse
agonists stabilize the inactive form. Neutral antagonists do not impact
the basal equilibrium but inhibit the activating effects of agonists. (B)
Intrinsic activities of b2AR ligands. Full agonists (like isoproterenol
and epinephrine) mediate a greater maximal effect than partial ago-
nists (like formoterol and albuterol). Neutral antagonists (like alpre-
nolol) have little intrinsic activitydpositive or negative. In contrast,
inverse agonists (like nadolol and to a lesser degree propranolol and
carvedilol) inhibit intrinsic activity to less than baseline levels. (C)
Effect of partial agonists, neutral antagonists, and inverse agonists on
full agonist-stimulated receptor responses.
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tween inverse agonists and neutral antagonists are yet to be
established in the treatment of hypertension (or in the
therapy of any cardiovascular disease).
4. Biased agonists are drugs that selectively favour the coupling
receptors to different downstream effector pathways. The
concept of biased agonism arose from the original observation
that b2AR could use b-arrestins to activate G-proteine
independent signalling and the activation of ERK1/2 phos-
phorylation.31,40,41 It is now clear that for many GPCRs,
including bARs, drugs that act as antagonists regarding the
activation of G-proteinedependent signalling can act as ag-
onists with respect to arrestin-dependent ERK1/2 phos-
phorylation. For example, it has been demonstrated that the
b-blocker carvedilol antagonizes the Gs-coupling of b2ARs
but stimulates GRK-mediated phosphorylation of the recep-
tor, b-arrestin recruitment, and ERK1/2 phosphorylation.44
This has led to the hypothesis that the unique efﬁcacy ofcarvedilol in the treatment of heart failuremaybe related to the
activation of b-arrestin signalling.
Regulation of bARs in Hypertension
b-Adrenergic blockade has been known as an effective
means of antihypertensive therapy for more than 50 years.
Intuitively, one might assume that the effectiveness of bAR
blockade in blood pressure control must reﬂect an underlying
bAR hyper-responsiveness as an important mechanism in the
pathogenesis/maintenance of hypertension. Overall adrenergic
activity as reﬂected by the net effect of sympathoadrenal
activation (ie, reﬂected by catecholamine release and receptor
responsiveness) is increased, at least in some patients with
hypertension, especially younger hypertensive patients.47
However, bAR function is depressed in hypertension.48Translational Signiﬁcance of the Impairment
of b-Adrenergic Responsiveness in the
Pathogenesis and Maintenance of the
Hypertensive State
The signiﬁcance of impaired b-adrenergic responsiveness in
hypertension has never been conclusively proved. However,
this impairment in vascular b-adrenergic responsiveness in
part contributes to the overall imbalance between vasocon-
strictor and vasodilator mechanisms that are characteristic of
the hypertensive state. Simplistically, one might consider
vascular resistance to reﬂect the net effects of hormonally
mediated vasodilator and vasoconstrictor forces, mostly
mediated by activation of GPCRs. Vasoconstrictor forces
would include the effects mediated by a range of neural,
endocrine, and paracrine hormones, including angiotensin II,
endothelin, catecholamines (through aARs), serotonin (by 5-
hydroxytryptamine 2), substance P, vasopressin, neuropeptide
Y, thromboxane A2, leukotrienes, and histamine (by H1 re-
ceptors). Similarly, regulation of vasodilator forces is mediated
by an overlapping set of GPCR-activating hormones,
including adenosine, glucagon, serotonin (through 5-
hydroxytryptamine 1 receptors), calcitonin gene-related pep-
tide, vasopressin, vasoactive intestinal peptide, prostanoids,
dopamine (through D1 and D5 receptors), histamine
(through H2 receptors), and bradykinin. Overall, in hyper-
tension the balance is shifted toward enhanced vasoconstrictor
forces.49 Hyper-responsiveness of some vasoconstrictor sys-
tems has been reported in hypertensive models. However, the
most consistent ﬁnding has been a defect in GPCR-mediated
vasodilatory forces.49 This has been characterized for a number
of GPCRs but has probably been best established for the bAR.
Despite baseline impairment in b-adrenergic response in
hypertension, it is notable that b-adrenergic antagonism is still
an effective therapeutic approach. This probably reﬂects several
considerations. First, the major effects of b-adrenergic antag-
onists in blood pressure regulation probably reﬂect their actions
in reducing cardiac output. Notably, b-adrenergicemediated
cardiac (primarily b1AR mediated) chronotropic and inotropic
responses (independent of the global impairment in cardiac
performance related to left ventricular hypertrophy/ventricular
stiffness) may be less impaired than vascular (primarily b2AR
mediated) vasodilator responses.50 Second, and as noted earlier,
notwithstanding the impairment in receptor responses, the net
b-adrenergic effect in hypertension, ie, the product of both
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increased in many groups of patients with hypertension,
especially younger patients with hypertension in whom b-
blockers are particularly effective.51,52 This predominantly re-
lates to higher levels of sympathetic activity.Molecular Basis of the Defect in bARs in
Hypertension
The mechanism underlying the defect in b-adrenergic re-
sponses in hypertensionwasﬁrst describedmore than 30 years ago
as an impairment in receptoreG-protein coupling.53 The defect
in bAR function follows a pattern of defective receptor-effector
coupling for a number of hormones linked to vasodilation
through activation of the stimulatory G-protein and consequent
adenylyl cyclase activation.54Thismolecular defect is paralleledby
the functional defect of impaired hormone-mediated vasodilatory
function for these receptor systems. Subsequently, the molecular
basis for this defect was identiﬁed as increased expression and
activity of GRK, as described earlier,55 the enzyme mediating
GPCR phosphorylation and subsequent desensitization.
The mechanism driving the increase in GRK2 expression and
activity in hypertension has yet to be identiﬁed. However, it is
notable that this defect inb-adrenergicemediated responses does
not appear to be secondary to the increase in sympathoadrenal
activity, which might be anticipated to result in a consequent
desensitization response. Thus, bAR function has been shown to
be increased to normal levels when hypertensive patients were fed
a low-sodium diet and despite a consequent increase in sympa-
thetic activity (as determined by plasma catecholamine concen-
trations), as determined both on a molecular basis and in the
context ofb-adrenergic vasodilator responses.56,57Theseﬁndings
suggest that the defect in b-adrenoceptor function is unrelated to
a “classic” process of agonist-mediated desensitization.Conclusions
The regulation of bAR function has remained an impor-
tant target in the management of hypertension. Further, the
success of this approach resulted in the focus on the molecular
basis of b-adrenergic effects. The importance of these studies
has been in the elucidation of b-adrenergic function and the
molecular basis of the impairment in bAR function in hy-
pertension and has also served as the paradigm for the more
global understanding of the molecular basis of cell signalling
by the GPCR superfamily.Funding Sources
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